Business Wire

Takeda Appoints Toshio Fujimoto, MD, MBA, as General Manager of the Health Innovation Park in Shonan

Del

Takeda Pharmaceutical Company Limited [TSE: 4502] announced today that Toshio Fujimoto, MD, MBA has been appointed General Manager of the Health Innovation Park in Shonan. The appointment is effective as of December 1, 2017. In this new role, Dr. Fujimoto, who joins Takeda from Eli Lilly Japan, will provide strategic leadership and oversight for all key Park activities, including: development and execution of business and financial plans, coordination of site operations and services, tenant recruitment and management, and marketing and public relations activities. Dr. Fujimoto will be accountable to a newly formed Management Board comprised of Takeda executives. The Management Board will be led by Seigo Izumo (Global Head of Regenerative Medicine Unit, Head of Scientific Affairs, Japan), who will serve as Chair, and will include Salvatore Alesci (Head of R&D Global Science and Biomedical Policy) and Haruhiko Hirate (Corporate Officer, Corporate Communications and Public Affairs Officer). The Management Board will provide counsel and support decision-making as Takeda continues to establish the Park’s ecosystem and maintain efforts to build meaningful collaborations with academic institutions, biotech and biopharmaceutical companies and other partners.

Dr. Fujimoto brings to Shonan diverse R&D experience, strong leadership skills and business acumen. In his most recent role as Vice President, Medicine Development Unit at Eli Lilly Japan – a position which he held since 2015, he oversaw the R&D Management function in Japan. Dr. Fujimoto received his MD from Kyoto University and his MBA from Kobe University. He began his clinical practice as a Resident in the Department of Thoracic Surgery at Kyoto University Hospital. After completing several rotations at local area hospitals, he took a position in Germany as Assistant Surgeon with the Thoracic Surgery Department at Ruhrlandklink Hospital, and later moved to the U.S. to serve as Clinical Fellow, General Thoracic Surgery at the Mayo Clinic.

“The appointment of Dr. Fujimoto as General Manager of our Health Innovation Park is an important milestone that signals to both our current and prospective partners, our continued commitment to promote an open innovation ecosystem in Japan,” said Andrew Plump, Chief Medical and Scientific Offer, Takeda. “I have every expectation that Dr. Fujimoto’s passion, leadership skills and R&D experience will be a tremendous asset in our efforts to build a vibrant and exciting community for industry, government and academia to incubate and accelerate the translation of cutting-edge science into impactful healthcare solutions for patients in Japan – and across the globe. I am excited to welcome him to our executive team.”

Takeda has committed significant resources to the development of its Health Innovation Park in Shonan as the Company seeks to establish the first openly innovative ecosystem built on pharmaceutical know-how in Japan.

Shonan Health Innovation Park Partners (as of 1st December)

  • T-CiRA
   
  • Axcelead Drug Discovery Partners, Inc.
  • Scohia, Inc.
  • Cardurion Pharmaceuticals.
  • Seedsupply, Inc.
  • ChromaJean, Inc.
  • Chordia Therapeutics, Inc.
  • Rabics, Inc.
  • K-Pharma, Inc.
  • Noile-Immune Biotech, Inc.
  • Oita University
    Institute of Advanced Medicine, Inc.
 

For more information about Takeda’s Innovation Ecosystem, visit Ecosystem for health innovation.

For more information about Shonan Health Innovation Park, visit shonan-health-innovation-park.com.

About Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in Emerging Markets, are currently fueling the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries. For more information, visit www.takeda.com/news.

Takeda’s Forward-Looking Statements

This press release contains “forward-looking statements.” Forward-looking statements include all statements other than statements of historical fact, including plans, strategies and expectations for the future, statements regarding the expected timing of filings and approvals relating to the transaction, the expected timing of the completion of the transaction, the ability to complete the transaction or to satisfy the various closing conditions, future revenues and profitability from or growth or any assumptions underlying any of the foregoing. Statements made in the future tense, and words such as “anticipate,” “expect,” “project,” “continue,” “believe,” “plan,” “estimate,” “pro forma,” “intend,” “potential,” “target,” “forecast,” “guidance,” “outlook,” “seek,” “assume,” “will,” “may,” “should,” and similar expressions are intended to qualify as forward-looking statements. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to: required regulatory approvals for the transaction may not be obtained in a timely manner, if at all; the conditions to closing of the transaction may not be satisfied; competitive pressures and developments; applicable laws and regulations; the success or failure of product development programs; actions of regulatory authorities and the timing thereof; changes in exchange rates; and claims or concerns regarding the safety or efficacy of marketed products or product candidates in development. The forward-looking statements contained in this press release speak only as of the date of this press release, and neither Portal Instruments nor Takeda undertake any obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If one or more of these statements is updated or corrected, investors and others should not conclude that additional updates or corrections will be made.

Contact information

Takeda Pharmaceutical Company Limited
Tatsuhiro Kanoo – Japan
Tatsuhiro.kanoo@takeda.com
+81 (0) 3-3278-3634
or
Kelly Schlemm – USA
kelly.schlemm@takeda.com
+1-617-551-8865

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ThreatMetrix Exceeds 45% Annual Growth as Organizations Embrace Digital Identity as Must-Have Technology18.12.2017 13:00Pressemelding

ThreatMetrix ®, The Digital Identity Company®, today announced 45 percent growth in billings year-on-year, as implementing digital identity solutions became a key priority for organizations in 2017. In the past quarter, average daily transaction volume processed by ThreatMetrix surged from 75 million to more than 100 million transactions, contributing rich data to the world’s only digital identity graph. Throughout 2017, nearly 150 new companies per quarter were added to the Digital Identity Network®, giving ThreatMetrix customers an unparalleled global view into true digital identity and user trust. “Organizations of all shapes and sizes are embracing ThreatMetrix ID™ to recognize true customers, operate digital businesses securely and profitably, and improve the user experience – all without compromising privacy,” says Frank Teruel, chief finance off

DWC Secures € 10,8 M From GEM Global18.12.2017 10:54Pressemelding

Diversified World Corporation 3.0 spa, (“DWC 3.0” or “the Company“) is a listed company at Euronext Access Market in Paris, Symbol (MLDWC:FP). Today, DWC 3.0 is pleased to announce that it has signed a contract for a € 10, 8 million funding facility under a three years warrants agreement, (the “Agreement”) with GEM Global Yield Fund, the private alternative investment group. These € 10,8 million will be raised by issuing 30 million warrants that can be exercised within three years by GEM Global Yield Fund, at the price which represents the nominal value of the share. The Company will sign within a very short time an agreement with a specialist sponsor in order to upgrade its listing to GROWTH Euronext Market in Paris. About DWC 3.0 The Company considers important its presence within the Fine Art sector since Merrill Lynch -Cap Gem

EURid Hosts Green Discussion Panel at The 2017 Internet Governance Forum in Geneva18.12.2017 10:00Pressemelding

EURid understands the importance that possessing a neutral carbon footprint has on the planet, which is why it has, and continues to support sustainable projects all over the world. Since May 2012, EURid has been Eco-Management and Audit Scheme (EMAS) certified, which reflects its continuous pursuit towards being a sustainable organisation. As part of its EMAS certification, EURid has issued and instituted an environmental policy, through which it has achieved the following goals: In 2015, EURid joined forces with the environmental Spanish non-profit organisation FAPAS. A number of fruit trees were planted in Asturias, Spain, an area populated by the endangered European brown bear. EURid also purchased verified CO2 credits to contribute to the Ecomapuà project with the goal of conserving the rich biodiversity in the Amazon.

BearingPoint Achieves Platinum Status in the Salesforce Consulting Partner Program18.12.2017 09:00Pressemelding

Management and technology consultancy BearingPoint is officially designated a Salesforce Platinum Consulting Partner. The prestigious Platinum Consulting Partner status marks an important milestone for the consultancy and demonstrates its commitment to help the world's most innovative brands enhance their customer experience and run their business in the cloud by leveraging the power of the Salesforce platform. With many new engagements this year, BearingPoint has also been able to significantly increase the number of Salesforce certifications while delivering great value to clients by integrating the Salesforce platform into their business. “Reaching the Platinum Consulting Partner status within less than 3 years basically coming from zero has been a huge feat and shows the focus, dedication, and energy of our fast-growing Salesforce community at BearingPoint,” says Markus

Timor Telecom Enhances International Voice Connections in Timor-Leste Through SES Networks18.12.2017 07:55Pressemelding

Timor Telecom (TT), the largest telecommunications operator in Timor-Leste, has expanded its partnership with SES Networks to enable international voice traffic between Timor-Leste and the rest of the world, SES announced today. Under the new agreement, TT will contract capacity on the high-powered NSS-12 geostationary earth orbit (GEO) satellite to establish a point-to-point link connecting Dili, Timor with Sintra, Portugal. Today, residents of Timor-Leste benefit from high speed 4G/LTE mobile data and broadband services provided by TT, which are powered by SES’s O3b medium earth orbit (MEO) satellite network. With its capacity uptake on NSS-12, TT will broaden its suite of services with the carriage of international voice traffic between Timor-Leste and the rest of the world. This enables TT to continue empowering local communities with superior services and to meet all th

Steeper Energy Announces EUR 50.6 M (DKK 377 M) Advanced Biofuel Project with Norwegian-Swedish joint venture Silva Green Fuel in Licensing Deal18.12.2017 07:00Pressemelding

Steeper Energy, a Danish-Canadian clean-fuel company, is partnering with Silva Green Fuel, a Norwegian-Swedish joint venture, to construct a EUR 50.6 M (DKK 377M) industrial scale demonstration plant at a former pulp mill located in Tofte, Norway leading to a future commercial scale project. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171217005029/en/ Steeper will license its proprietary Hydrofaction™ technology to Silva, who will build the facility over the next 18 months. The demonstration plant will use woody residues as feedstock that are converted to renewable crude oil and, in turn, will be upgraded to renewable diesel, jet or marine fuel. Steeper’s Hydrofaction™ technology was selected by Silva after an exhaustive due diligence review of some 40 other technologies. Hydrofaction™ harnesses water

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom